Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AZD2936 + Capecitabine + Oxaliplatin + Trastuzumab |
| Synonyms | Rilvegostomig + Trastuzumab + CAPOX |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AZD2936 | AZD-2936|AZD 2936|Rilvegostomig | PD-L1/PD-1 antibody 132 TIGIT Antibody 20 | AZD2936 is a bispecific antibody that targets T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT) and PD-1 (PDCD1), which potentially leads to increased T-lymphocyte antitumor activity, tumor cell killing, and inhibition of tumor growth (Journal for ImmunoTherapy of Cancer 2022;10). | |
| Capecitabine | Xeloda | R340 | Chemotherapy - Antimetabolite 14 | Xeloda (capecitabine) is an antimetabolite that when activated to 5-FU ultimately inhibits DNA synthesis and cell division (NCI Drug Dictionary). |
| Oxaliplatin | Eloxatin | Diaminocyclohexane Oxalatoplatinum | Chemotherapy - Platinum 7 | Eloxatin (oxaliplatin) is comprised of a platinum complex, which causes DNA-platinum cross-links, inhibition of DNA replication and transcription, and cell toxicity, and is FDA approved for colorectal cancer (FDA.gov). |
| Trastuzumab | Herceptin | Anti HER2 | HER2 (ERBB2) Antibody 79 | Herceptin (trastuzumab) is a monoclonal antibody, which binds ERBB2 (HER2) to induce tumor cellular cytotoxicity (PMID: 17611206). Herceptin (trastuzumab) is FDA approved for HER2-overexpressing (or amplification) breast cancer, gastric adenocarcinoma, and gastroesophageal junction adenocarcinoma (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06764875 | Phase III | Capecitabine + Oxaliplatin + Pembrolizumab + Trastuzumab Cisplatin + Fluorouracil + Pembrolizumab + Trastuzumab AZD2936 + Capecitabine + Oxaliplatin + Trastuzumab AZD2936 + Cisplatin + Fluorouracil + Trastuzumab AZD2936 + Fluorouracil + Trastuzumab deruxtecan AZD2936 + Capecitabine + Trastuzumab deruxtecan | A Phase III Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer | Recruiting | USA | TUR | POL | NLD | ITA | HUN | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUT | AUS | ARG | 12 |